Ernexa Therapeutics Inc. (ERNA) Capital Leases (2010 - 2022)

Ernexa Therapeutics' (ERNA) quarterly Capital Leases came in at $6000.0 in Q3 2022, up 50.0% on a QoQ basis from $4000.0 in Q3 2020.

Ernexa Therapeutics Inc. (ERNA) Capital Leases (2010 - 2022) Analysis & Trends

Ernexa Therapeutics (ERNA) has 12 years of Capital Leases data on file, last reported at $6000.0 in Q3 2022.

Quarterly Capital Leases changed N/A year-over-year to $6000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $6000.0 (changed N/A YoY) and the FY2019 annual result came in at $20000.0, down 51.22% from the prior year.
Capital Leases grew to $6000.0 in Q3 2022, from $4000.0 in the prior quarter.
In the past five years, Capital Leases ranged from a high of $114000.0 in Q1 2018 to a low of $4000.0 in Q3 2020.
A 4-year average of $37300.0 and a median of $28000.0 in 2019 frame the typical range for Capital Leases.
Annual changes were most pronounced in 2018 — Capital Leases plunged 48.18% — and 2020, when it slumped 84.0%.
Tracing ERNA's Capital Leases over 4 years: stood at $41000.0 in 2018, then slumped by 51.22% to $20000.0 in 2019, then tumbled by 80.0% to $4000.0 in 2020, then jumped by 50.0% to $6000.0 in 2022.
The last three Capital Leases figures came in at $6000.0 (Q3 2022), $4000.0 (Q3 2020), and $15000.0 (Q1 2020), per Business Quant data.

Download Data